1. Home
  2. VLY vs IKT Comparison

VLY vs IKT Comparison

Compare VLY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

HOLD

Current Price

$12.55

Market Cap

8.1B

Sector

Finance

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.02

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLY
IKT
Founded
1927
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
220.5M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
VLY
IKT
Price
$12.55
$2.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
5
Target Price
★ $14.65
$5.00
AVG Volume (30 Days)
★ 6.2M
388.2K
Earning Date
04-23-2026
03-26-2026
Dividend Yield
★ 3.31%
N/A
EPS Growth
46.38
★ 57.76
EPS
★ 0.57
N/A
Revenue
N/A
N/A
Revenue This Year
$23.58
N/A
Revenue Next Year
$8.51
N/A
P/E Ratio
$22.42
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.64
$1.33
52 Week High
$15.20
$2.61

Technical Indicators

Market Signals
Indicator
VLY
IKT
Relative Strength Index (RSI) 26.74 31.78
Support Level $11.53 $1.59
Resistance Level $15.00 $2.13
Average True Range (ATR) 0.31 0.10
MACD -0.08 -0.04
Stochastic Oscillator 1.66 16.49

Price Performance

Historical Comparison
VLY
IKT

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: